Analisi di impatto di budget di pasireotide in pazienti con Acromegalia nella prospettiva del Servizio Sanitario Nazionale

Autori

  • Francesco Saverio Mennini Economic Evaluation and HTA (CEIS- EEHTA). Faculty of Economics, University of Rome “Tor Vergata”, Italy. Institute for Leadership and Management in Health - Kingston University London, London, UK
  • Andrea Marcellusi National Research Council (CNR), Institute for Research on Population and Social Policies (IRPPS)
  • Fabio Palazzo National Research Council (CNR), Institute for Research on Population and Social Policies (IRPPS).
  • Giampiero Favato Institute for Leadership and Management in Health - Kingston University London, London, UK
  • Raffaella Viti Economic Evaluation and HTA (CEIS- EEHTA). Faculty of Economics, University of Rome “Tor Vergata”, Italy.
  • Chiara Bini Economic Evaluation and HTA (CEIS- EEHTA). Faculty of Economics, University of Rome “Tor Vergata”, Italy.
  • Pietro Maffei Azienda Ospedaliera di Padova, Clinica Medica 3^, DIMED
  • Rosario Pivonello Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli

DOI:

https://doi.org/10.14600/irpps_wps.101.2017

Parole chiave:

Valutazione tecnologie sanitarie, Analisi di Budget, Acromegalia, Signifor

Abstract

Background: L’obiettivo dell’analisi è stato quello di valutare l’impatto economico dell’introduzione di pasireotide nella prospettiva del Servizio Sanitario Nazionale (SSN). Metodi: I dati epidemiologici e di costo che hanno implementato il modello di budget impact (BI) sono stati ottenuti tramite una revisione sistematica della letteratura. Il BI è stato stimato confrontando uno scenario senza l’introduzione di pasireotide rispetto ad uno scenario con nella prospettiva del SSN. Inoltre, è stata sviluppate una analisi di sensibilità deterministica (DSA) e l’applicazione del metodo payoff. Risultati: Il modello ha stimato un totale di circa 2.314 pazienti acromegalici ad oggi trattati con una seconda linea farmacologica. L’introduzione di pasireotide consente una riduzione complessiva di spesa pari a € 662.095 nei 5 anni di analisi. La DSA ed il valore atteso di pay-off confermano la robustezza dei risultati. Conclusioni: L’introduzione sul mercato di pasireotide non comporta un aggravio di spesa per il SSN, ma genera una reale riduzione dei costi.

Riferimenti bibliografici

Ayuk, J., and M. C. Sheppard. 2008. 'Does acromegaly enhance mortality?', Reviews in Endocrine and Metabolic Disorders, 9: 33-39.

Broder, M. S., E. Chang, D. Cherepanov, MP. Neary, and W. H. Ludlam. 2016. 'Incidence and prevalence of Acromegaly in the United States: a claims-based analysis', Endocrine Practice.

Brown, C. K., M. J. Sampson, R. H. Greenwood, P. J. Heyburn, and R. C. Temple. 2003. 'Acromegaly: A study of epidemiological characteristics and treatment outcomes', Endocrine Abstracts, 5: 124.

Casagrande, A., M. D. Bronstein, R. S. Jallad, J. I. Mota, A. Tabet, and J. Abucham. 2016. 'Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study', J Endocrinol Invest.

Chanson, P., and S. Salenave. 2008. 'Acromegaly', Orphanet Journal of Rare Diseases.

Colao, A. 2009. '5 Long-term acromegaly and associated cardiovascular complications: a case-based review', Best Practice & Research Clinical Endocrinology & Metabolism, 23, Supplement 1: S31-S38.

Colao, A., R. S. Auriemma, G. Lombardi, and R. Pivonello. 2011. 'Resistance to Somatostatin Analogs in Acromegaly', Endocrine Reviews, 32.

Colao, A., D. Ferone, P. Marzullo, and G. Lombardi. 2004. 'Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management', Endocrine Reviews, 25: 102-52.

Collan, M., T. Haahtela, and K. Kyläheiko. 2016. 'On the usability of real option valuation model types under different types of uncertainty', Int. J. Business Innovation and Research, 11.

Daly, A.F., P. Petrossians, and A. Beckers. 2005. 'An overview of the epidemiology and genetics of acromegaly', Journal of Endocrinological Investigation, 28: 67-9.

Didoni, G., S. Grottoli, V. Gasco, M. Battistini, D. Ferone, M. Giusti, F. Ragazzoni, P. Ruffo, E. Ghigo, and F. Minuto. 2004. 'Cost-of-illness study in acromegalic patients in Italy', Journal of Endocrinological Investigation, 27: 1034-9.

Favato, G., G. Baio, A. Capone, A. Marcellusi, and F. S. Mennini. 2013. 'A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy', Clinical Therapeutics, 35: 904-14.

Fernandez, A., N. Karavitaki, and J. A. Wass. 2010. 'Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)', Clinical Endocrinology, 72: 377–82.

Gadelha, M. R., M. D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K. K. Lievre, J. Fleck, M. Aout, A. M. Pedroncelli, A. Colao, and C. Study Group Pasireotide. 2014. 'Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial', Lancet Diabetes Endocrinol, 2: 875-84.

Giustina, A., P. Chanson, M. D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, K. Ghigo, K. Ho, and S. Melmed. 2010. 'A consensus on Criteria for Cure of Acromegaly', The Journal of Clinical Endocrinology & Metabolism, 95: 3141–48.

Grottoli, S., P. Maffei, F. Bogazzi, S. Cannavo, A. Colao, E. Ghigo, R. Gomez, E. Graziano, M. Monterubbianesi, P. Jonsson, and L. De Marinis. 2015. 'ACROSTUDY: the Italian experience', Endocrine, 48: 334-41.

Istituto Nazionale di Statistica (ISTAT). 2015. 'Popolazione residente al 1 Gennaio 2014'. http://demo.istat.it/.

Jallad, R. S., and M. D. Bronstein. 2009. 'Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide', Neuroendocrinology, 90: 82-92.

Mauskopf, J. A., S. D. Sullivan, L. Annemans, J. Caro, C. D. Mullins, M.

Nuijten, E. Orlewska, J. Watkins, and P. Trueman. 2007. 'Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis', Value Health, 10: 336-47.

Melmed, S., A. Colao, A. Barkan, M. Molitch, A. B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M. L. Vance, K. Ho, and A. Giustina. 2009. 'Guidelines for Acromegaly Management: An Update', The Journal of Clinical Endocrinology & Metabolism, 94: 1509–17.

Mercieca, C., M. Gruppetta, and J. Vassallo. 2012. 'Epidemiology, treatment trends and outcomes of acromegaly', European Journal of Internal Medicine, 23: e206-7.

Pereira, A. M., S. W. van Thiel, J. R. Lindner, F. Roelfsema, E. E. van der Wall, H. Morreau, J. W. Smit, J. A. Romijn, and J. J. Bax. 2004. 'Increased prevalence of regurgitant valvular heart disease in acromegaly', The Journal of Clinical Endocrinology & Metabolism, 89: 71-5.

Petersenn, S., J. Schopohl, A. Barkan, P. Mohideen, A. Colao, R. Abs, A. Buchelt, Y. Y. Ho, K. Hu, A. J. Farrall, S. Melmed, and B.M. Biller. 2010. 'Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial', The Journal of Clinical Endocrinology & Metabolism, 95: 2781-9.

Rowles, S. V., L. Prieto, X. Badia, S. M. Shalet, S. M. Webb, and P. J. Trainer. 2005. 'Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire', The Journal of Clinical Endocrinology & Metabolism, 90: 3337-41.

Suda, K., N. Inoshita, G. Iguchi, H. Fukuoka, M. Takahashi, H. Nishizawa, M. Yamamoto, S. Yamada, and Y. Takahashi. 2013. 'Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature', Endocr J, 60: 507-15.

Sullivan, S. D., J.A. Mauskopf, F. Augustovski, J. Jaime Caro, K. M. Lee, M. Minchin, E. Orlewska, P. Penna, J. M. Rodriguez Barrios, and W. Y. Shau. 2014. 'Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force', Value Health, 17: 5-14.

Trainer, P. J., S. Ezzat, G. A. D'Souza, G. Layton, and C.J. Strasburger. 2009. 'A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly', Clinical Endocrinology (Oxf), 71: 549-57.

Vilar, L., M. F. Azevedo, L. A. Naves, L. A. Casulari, J. L. Albuquerque, R. M. Montenegro, R. M. Montenegro, Jr., P. Figueiredo, G. C. Nascimento, and M. S. Faria. 2011. 'Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR', Pituitary, 14: 148-56.

##submission.downloads##

Pubblicato

2017-10-25

Come citare

Mennini, F. S., Marcellusi, A., Palazzo, F., Favato, G., Viti, R., Bini, C., Maffei, P., & Pivonello, R. (2017). Analisi di impatto di budget di pasireotide in pazienti con Acromegalia nella prospettiva del Servizio Sanitario Nazionale. IRPPS Working Papers, 1–30. https://doi.org/10.14600/irpps_wps.101.2017

Fascicolo

IRPPS WPs pubblicati nel 2017

Sezione

Working Papers

Licenza

Questa licenza permette a terzi di riprodurre, distribuire, comunicare al pubblico, esporre in pubblico, rappresentare, eseguire, recitare e modificare quest'opera, purché vengano citati l'autore e la fonte. Questa è la più ampia tra le licenze Creative Commons, rispetto alle libertà concesse a terzi sulle opere licenziate sotto attribuzione.